Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2025 Earnings Call Transcript February 12, 2026 Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager for B-cell mediated autoimmune diseases. The collaboration focuses on ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) has signed a license and research agreement with WuXi Biologics for a trispecific T cell engager targeting B cell mediated autoimmune diseases. The deal gives ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best high growth high margin stocks to buy now. On January 28, Barclays began coverage of Vertex Pharmaceuticals Incorporated ...

CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.

FDA vouchers are normally a coveted prize for biopharma companies, but a surprise rejection for Disc Medicine’s rare disease drug has biopharma reconsidering.

A governance layer (VirtueGov) helps businesses enforce standards, uphold compliance requirements and meet internal policies across AI deployments and agents. The platform also includes tools to ...

Vertex, Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced financial results ...

Jupiter Endovascular, Inc. announced completion of patient enrollment in the SPIRARE II pivotal clinical trial evaluating the c ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is among the most profitable healthcare stocks to buy. On January 26, UBS increased the price target on Vertex Pharmaceuticals Incorporated ...